SCHEMBL1925550

SCHEMBL1925550

CCCCCc1ccn(CCCCC)c1CCCCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 7/20 0.40
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
HTT P42858 6/20 0.38
LMNA P02545 3/20 0.38
APOBEC3A P31941 2/20 0.38
APOBEC3G Q9HC16 2/20 0.38
ALDH1A1 P00352 2/20 0.38
PABPC1 P11940 1/20 0.38
GALR3 O60755 2/20 0.37
POLB P06746 2/20 0.37
ATM Q13315 2/20 0.37
MAPK1 P28482 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPT P10636 2/20 0.37
LIPG Q9Y5X9 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSP90AA1 P07900 1/20 0.37
RAD52 P43351 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10538607 0.83 ALDH1A1 (0.39) TLR8NPC1RAB9AHTTLMNA
SCHEMBL10755003 0.80 TLR8 (0.39) TLR8NPC1RAB9AHTTLMNA
SCHEMBL28179444 0.78 KCNA3 (0.46) TLR8NPC1ALDH1A1MAPK1LIPG
SCHEMBL9679895 0.76 HSD17B10 (0.37) TLR8NPC1RAB9AHTTLMNA
SCHEMBL10539640 0.73 ALDH1A1 (0.40) TLR8NPC1RAB9AHTTLMNA
SCHEMBL2968938 0.70 ALDH1A1 (0.38) TLR8NPC1RAB9AHTTLMNA
SCHEMBL2974162 0.70 TYR (0.38) TLR8HTTLMNAALDH1A1POLB
SCHEMBL27155129 0.69 KDM4E (0.37) TLR8HTTLMNAALDH1A1SMN1; SMN2
Bromide SCHEMBL29212810 0.69 NPC1 (0.43) TLR8NPC1RAB9AHTTLMNA
SCHEMBL23691650 0.68 ALDH1A1 (0.43) TLR8NPC1RAB9AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005024058-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES INVOLVING COGNITIVE IMPAIRMENT, SUCH AS ALZHEIMER’S DISEASE, AND METHODS FOR IDENTIFYING SUCH COMPOUNDS GALAPAGOS N.V. (BE) 2005-03-17 WO claimed
CN-116348105-A Pharmaceutically acceptable salts of arylpyrrole derivatives 圣提内尔肿瘤学有限公司 2023-06-27 CN disclosed
CN-114585605-A Pharmaceutical compounds 圣提内尔肿瘤学有限公司 2022-06-03 CN disclosed
EP-1431293-B1 WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2011-06-08 EP disclosed
US-20090270399-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2009-10-29 US disclosed
EP-1043317-B1 PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT KOWA CO (JP) 2009-04-15 EP disclosed
US-20090069332-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2009-03-12 US disclosed
EP-2017266-A1 Pyridazine derivatives and medicines containing the same as effective ingredients Kowa Co., Ltd. (JP) 2009-01-21 EP disclosed
US-20080119474-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2008-05-22 US disclosed
US-20070208025-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2007-09-06 US disclosed
EP-1196167-A1 METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS Lipton, Stuart A. (US) 2002-04-17 EP disclosed
US-6348468-B1 THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. KOWA CO., LTD. (JP) 2002-02-19 US disclosed
EP-1178981-A1 SUBSTITUTED 3-PYRIDYL-4-ARYLPYRROLES, AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS Ortho-Mcneil Pharmaceutical, Inc. (US) 2002-02-13 EP disclosed
EP-1156039-A1 PYRIDAZIN-3-ONE DERIVATIVES AND MEDICINES CONTAINING THE SAME Kowa Co., Ltd. (JP) 2001-11-21 EP disclosed
WO-2001001986-A1 METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS LIPTON STUART A (US) 2001-01-11 WO disclosed
EP-1061077-A1 NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Kowa Co., Ltd. (JP) 2000-12-20 EP disclosed
WO-2000069847-A1 SUBSTITUTED 3-PYRIDYL-4-ARYLPYRROLES, AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-11-23 WO disclosed
EP-1043317-A1 NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Kowa Co., Ltd. (JP) 2000-10-11 EP disclosed
US-5387693-A Intermediates for inhibitors of cholesterol biosynthesis ORTHO PHARMACEUTICAL CORPORATION (US) 1995-02-07 US disclosed
US-5134155-A Anticholesterol ORTHO PHARMACEUTICAL CORPORATION (US) 1992-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208025-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TLR8 120/4885NPC1 957/4885RAB9A 4271/4885
US-20090270399-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TLR8 113/4885NPC1 1058/4885RAB9A 4323/4885
US-20090069332-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TLR8 113/4885NPC1 1058/4885RAB9A 4323/4885
US-20080119474-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TLR8 120/4885NPC1 957/4885RAB9A 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.